Compare Cadila Healthcare with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs PFIZER - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE PFIZER CADILA HEALTHCARE/
PFIZER
 
P/E (TTM) x 24.9 42.4 58.7% View Chart
P/BV x 4.4 7.0 62.0% View Chart
Dividend Yield % 0.8 0.5 163.0%  

Financials

 CADILA HEALTHCARE   PFIZER
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
PFIZER
Mar-19
CADILA HEALTHCARE/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3523,840 9.2%   
Low Rs2072,080 9.9%   
Sales per share (Unadj.) Rs139.2455.0 30.6%  
Earnings per share (Unadj.) Rs11.893.8 12.5%  
Cash flow per share (Unadj.) Rs18.6109.4 17.0%  
Dividends per share (Unadj.) Rs3.5022.50 15.6%  
Dividend yield (eoy) %1.30.8 164.8%  
Book value per share (Unadj.) Rs101.4658.2 15.4%  
Shares outstanding (eoy) m1,023.7445.75 2,237.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.06.5 30.8%   
Avg P/E ratio x23.731.6 75.2%  
P/CF ratio (eoy) x15.027.1 55.6%  
Price / Book Value ratio x2.84.5 61.3%  
Dividend payout %29.824.0 124.0%   
Avg Mkt Cap Rs m286,033135,420 211.2%   
No. of employees `00013.42.6 509.5%   
Total wages/salary Rs m24,1453,238 745.6%   
Avg. sales/employee Rs Th10,632.77,911.4 134.4%   
Avg. wages/employee Rs Th1,801.21,230.9 146.3%   
Avg. net profit/employee Rs Th898.51,630.7 55.1%   
INCOME DATA
Net Sales Rs m142,53120,815 684.8%  
Other income Rs m1,1391,674 68.0%   
Total revenues Rs m143,67022,489 638.8%   
Gross profit Rs m24,1985,712 423.6%  
Depreciation Rs m6,965714 975.6%   
Interest Rs m3,41873 4,688.6%   
Profit before tax Rs m14,9546,599 226.6%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1982,309 138.5%   
Profit after tax Rs m12,0444,291 280.7%  
Gross profit margin %17.027.4 61.9%  
Effective tax rate %21.435.0 61.1%   
Net profit margin %8.520.6 41.0%  
BALANCE SHEET DATA
Current assets Rs m87,15427,167 320.8%   
Current liabilities Rs m82,6948,917 927.4%   
Net working cap to sales %3.187.7 3.6%  
Current ratio x1.13.0 34.6%  
Inventory Days Days7168 105.3%  
Debtors Days Days9430 311.6%  
Net fixed assets Rs m133,2368,862 1,503.5%   
Share capital Rs m1,024458 223.8%   
"Free" reserves Rs m102,73329,656 346.4%   
Net worth Rs m103,75730,113 344.6%   
Long term debt Rs m32,14625 128,584.0%   
Total assets Rs m236,86639,400 601.2%  
Interest coverage x5.491.5 5.9%   
Debt to equity ratio x0.30 37,318.9%  
Sales to assets ratio x0.60.5 113.9%   
Return on assets %6.511.1 58.9%  
Return on equity %11.614.2 81.5%  
Return on capital %13.722.1 62.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,752428 12,316.6%   
Fx outflow Rs m14,504786 1,844.4%   
Net fx Rs m38,248-358 -10,680.8%   
CASH FLOW
From Operations Rs m25,054978 2,561.5%  
From Investments Rs m-10,123351 -2,882.4%  
From Financial Activity Rs m-10,942-1,099 996.1%  
Net Cashflow Rs m3,989231 1,728.3%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 8.3 7.5 110.7%  
FIIs % 5.9 4.9 120.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 23.7 46.4%  
Shareholders   44,069 85,207 51.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE SCIENCES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 441 Points Lower; Nifty Settles Below 15,000-Mark(Closing)

Indian share markets witnessed huge selling during closing hours today and ended their day lower.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Mar 5, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - DR. REDDYS LAB COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS